<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abrahantes, José Cortiñas</style></author><author><style face="normal" font="default" size="100%">Aerts, Marc</style></author><author><style face="normal" font="default" size="100%">van Everbroeck, Bart</style></author><author><style face="normal" font="default" size="100%">Saegerman, Claude</style></author><author><style face="normal" font="default" size="100%">Berkvens, Dirk</style></author><author><style face="normal" font="default" size="100%">Geys, Helena</style></author><author><style face="normal" font="default" size="100%">Mintiens, Koen</style></author><author><style face="normal" font="default" size="100%">S. Roels</style></author><author><style face="normal" font="default" size="100%">Cras, Patrick</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Classification of sporadic Creutzfeldt-Jakob disease based on clinical and neuropathological characteristics.</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Epidemiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Eur. J. Epidemiol.</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">brain</style></keyword><keyword><style  face="normal" font="default" size="100%">Creutzfeldt-Jakob Syndrome</style></keyword><keyword><style  face="normal" font="default" size="100%">Dementia</style></keyword><keyword><style  face="normal" font="default" size="100%">Diagnosis, Differential</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Population Surveillance</style></keyword><keyword><style  face="normal" font="default" size="100%">Predictive Value of Tests</style></keyword><keyword><style  face="normal" font="default" size="100%">Retrospective Studies</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">22</style></volume><pages><style face="normal" font="default" size="100%">457-65</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Creutzfeldt-Jakob disease (CJD) is a rare and fatal neurodegenerative disease of unknown cause. Patients are usually aged between 50 and 75 and typical clinical features include rapidly progressive dementia associated with myoclonus and a characteristic electroencephalographic pattern. Neuropathological examination reveals cortical spongiform change, hence the term 'spongiform encephalopathy'. Several statistical techniques were applied to classify patients with sporadic CJD (sCJD), based on clinical and neuropathological investigation. We focus on the classification of neuropathologically confirmed sCJD patients. In order to obtain a classification rule that correctly classifies this type of patients and at the same time controls the overall error rate, we apply several classification techniques, which in general, produce comparable results. The boosting method produces the best results and the variable 14-3-3 protein in cerebrospinal fluid plays the most important role in the prediction of neuropathologically confirmed sCJD.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">7</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/17587185?dopt=Abstract</style></custom1></record></records></xml>